Limits...
Adjunctive Treatment with Rhodiola Crenulata in Patients with Chronic Obstructive Pulmonary Disease--A Randomized Placebo Controlled Double Blind Clinical Trial.

Chuang ML, Wu TC, Wang YT, Wang YC, Tsao TC, Wei JC, Chen CY, Lin IF - PLoS ONE (2015)

Bottom Line: Over the 12 weeks, RC was well tolerated, significantly reduced triceps skin thickness (Δ=-1 mm, p=.04), change of FEV1 (4.5%, p=.03), and improved workload (Δ=10%, p=.01); although there were no significant differences in these factors between the two groups.RC did not improve the six-minute walk test distance but significantly improved tidal breathing and ventilation efficiency, most likely through improvements in work rate.Further studies with a larger patient population are needed in order to confirm these findings.

View Article: PubMed Central - PubMed

Affiliation: Division of Pulmonary Medicine and Department of Critical Care Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, Taiwan.

ABSTRACT

Unlabelled: Chronic obstructive pulmonary disease (COPD) is a low grade systemic inflammatory disease characterized by dyspnea and exercise intolerance even under standard therapy. Rhodiola crenulata (RC) has been shown to exert anti-inflammatory effects and to enhance exercise endurance, thereby having the potential to treat COPD. In this 12-week, randomized, double-blind, placebo-controlled clinical trial, 57 patients with stable moderate-to-severe COPD aged 70±8.8 years were given RC (250 mg twice/day) (n=38) or a placebo (250 mg twice/day) (n=19) in addition to their standard regimen. There were no significant differences in anthropometrics, quality of life, lung function, six-minute walk and incremental exercise tests between the two groups at enrollment. Over the 12 weeks, RC was well tolerated, significantly reduced triceps skin thickness (Δ=-1 mm, p=.04), change of FEV1 (4.5%, p=.03), and improved workload (Δ=10%, p=.01); although there were no significant differences in these factors between the two groups. However, there were significant between-group differences in tidal volume and ventilation-CO2-output ratio at peak exercise (both p=.05), which were significantly related to peak work rate (both p<.0001). RC tended to protect against acute exacerbation of COPD (p=.1) but not other measurements. RC did not improve the six-minute walk test distance but significantly improved tidal breathing and ventilation efficiency, most likely through improvements in work rate. Further studies with a larger patient population are needed in order to confirm these findings.

Trial registration: ClinicalTrials.gov number NCT02242461.

No MeSH data available.


Related in: MedlinePlus

Differences in the selected variables from the six-minute walk test between the Rhodiola crenulata group and placebo (PBO) group over the 12-week treatment period.*comparison within group: p < .05, comparisons between groups: all p >.05. Solid square symbol: baseline test of the study group, open square symbol: test at 12 weeks of the study group, solid circle symbol: baseline test of the placebo group, open circle symbol: test at 12 weeks of the placebo group, bars: standard error.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4476627&req=5

pone.0128142.g002: Differences in the selected variables from the six-minute walk test between the Rhodiola crenulata group and placebo (PBO) group over the 12-week treatment period.*comparison within group: p < .05, comparisons between groups: all p >.05. Solid square symbol: baseline test of the study group, open square symbol: test at 12 weeks of the study group, solid circle symbol: baseline test of the placebo group, open circle symbol: test at 12 weeks of the placebo group, bars: standard error.

Mentions: Over the 12 weeks, RC did not improve 6MWD (Fig 2, Δ = -7.5 meters, p = .23), and there was no change in heart rate at the end of the 6MWT (Fig 2, Δ = -.4 b/min, p = .6). The placebo also did not improve 6MWD but significantly increased heart rate at the end of the 6MWT (Δ = 9 b/min, p = .03). There were no significant differences in 6MWD over the 12-week study period between the two groups (Fig 2, all p>.05).


Adjunctive Treatment with Rhodiola Crenulata in Patients with Chronic Obstructive Pulmonary Disease--A Randomized Placebo Controlled Double Blind Clinical Trial.

Chuang ML, Wu TC, Wang YT, Wang YC, Tsao TC, Wei JC, Chen CY, Lin IF - PLoS ONE (2015)

Differences in the selected variables from the six-minute walk test between the Rhodiola crenulata group and placebo (PBO) group over the 12-week treatment period.*comparison within group: p < .05, comparisons between groups: all p >.05. Solid square symbol: baseline test of the study group, open square symbol: test at 12 weeks of the study group, solid circle symbol: baseline test of the placebo group, open circle symbol: test at 12 weeks of the placebo group, bars: standard error.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4476627&req=5

pone.0128142.g002: Differences in the selected variables from the six-minute walk test between the Rhodiola crenulata group and placebo (PBO) group over the 12-week treatment period.*comparison within group: p < .05, comparisons between groups: all p >.05. Solid square symbol: baseline test of the study group, open square symbol: test at 12 weeks of the study group, solid circle symbol: baseline test of the placebo group, open circle symbol: test at 12 weeks of the placebo group, bars: standard error.
Mentions: Over the 12 weeks, RC did not improve 6MWD (Fig 2, Δ = -7.5 meters, p = .23), and there was no change in heart rate at the end of the 6MWT (Fig 2, Δ = -.4 b/min, p = .6). The placebo also did not improve 6MWD but significantly increased heart rate at the end of the 6MWT (Δ = 9 b/min, p = .03). There were no significant differences in 6MWD over the 12-week study period between the two groups (Fig 2, all p>.05).

Bottom Line: Over the 12 weeks, RC was well tolerated, significantly reduced triceps skin thickness (Δ=-1 mm, p=.04), change of FEV1 (4.5%, p=.03), and improved workload (Δ=10%, p=.01); although there were no significant differences in these factors between the two groups.RC did not improve the six-minute walk test distance but significantly improved tidal breathing and ventilation efficiency, most likely through improvements in work rate.Further studies with a larger patient population are needed in order to confirm these findings.

View Article: PubMed Central - PubMed

Affiliation: Division of Pulmonary Medicine and Department of Critical Care Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, Taiwan.

ABSTRACT

Unlabelled: Chronic obstructive pulmonary disease (COPD) is a low grade systemic inflammatory disease characterized by dyspnea and exercise intolerance even under standard therapy. Rhodiola crenulata (RC) has been shown to exert anti-inflammatory effects and to enhance exercise endurance, thereby having the potential to treat COPD. In this 12-week, randomized, double-blind, placebo-controlled clinical trial, 57 patients with stable moderate-to-severe COPD aged 70±8.8 years were given RC (250 mg twice/day) (n=38) or a placebo (250 mg twice/day) (n=19) in addition to their standard regimen. There were no significant differences in anthropometrics, quality of life, lung function, six-minute walk and incremental exercise tests between the two groups at enrollment. Over the 12 weeks, RC was well tolerated, significantly reduced triceps skin thickness (Δ=-1 mm, p=.04), change of FEV1 (4.5%, p=.03), and improved workload (Δ=10%, p=.01); although there were no significant differences in these factors between the two groups. However, there were significant between-group differences in tidal volume and ventilation-CO2-output ratio at peak exercise (both p=.05), which were significantly related to peak work rate (both p<.0001). RC tended to protect against acute exacerbation of COPD (p=.1) but not other measurements. RC did not improve the six-minute walk test distance but significantly improved tidal breathing and ventilation efficiency, most likely through improvements in work rate. Further studies with a larger patient population are needed in order to confirm these findings.

Trial registration: ClinicalTrials.gov number NCT02242461.

No MeSH data available.


Related in: MedlinePlus